uploads///SYk ana reco

What Analysts Recommend for Stryker Stock

Kenneth Smith - Author

Oct. 19 2018, Updated 10:32 a.m. ET

Analyst recommendations

Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating. The mean rating for Stryker is 1.93 with a target price of $187.27, which implies an upside potential of 8.2% over Stryker’s closing price of $173.1 on October 18.

In comparison, peers Baxter International (BAX), Boston Scientific (BSX), and Zimmer Biomet Holdings (ZBH) have a mean rating of 2.41x, 1.52x, and 2.31x, respectively, and a target price of $79.79, $41.57, and $136.92, respectively.

Article continues below advertisement
Article continues below advertisement

Price performance

After a strong run up from $148.01 on February 8 to a high of $179.78 on June 6, Stryker stock has been within a range of $162 and $179 over the last three months. In the past one week, Stryker stock has witnessed buying interest and is trading at the present $173 levels.

The enterprise value of Stryker is $71.19 billion, and its enterprise value-to-revenue ratio is 5.46x. The stock is trading at a forward price-to-earnings multiple of 21.77x. Its price-to-sales ratio and price-to-book ratios are 4.96x and 6.84x, respectively.

The current ratio of Stryker, a metric of how effectively a company can meet its short-term obligations, stands at 1.80x. In comparison, the current ratio of peers Baxter International (BAX), Boston Scientific (BSX), and Zimmer Biomet Holdings (ZBH) stand at 2.60x, 0.80x, and 2.40x, respectively.


Latest Zimmer Holdings Inc News and Updates

    Opt-out of personalized ads

    © Copyright 2023 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.